share_log

Johnson & Johnson | 3: Initial statement of beneficial ownership of securities-10% Owner JOHNSON & JOHNSON

SEC announcement ·  Apr 11 05:06
Summary by Futu AI
Johnson & Johnson, a major healthcare company, has filed an SEC Form 3 indicating an initial statement of beneficial ownership of securities. The filing, dated 04/09/2024, reveals that Johnson & Johnson, through its wholly-owned subsidiary Johnson & Johnson Innovation - JJDC, Inc., has become a 10% owner of Contineum Therapeutics, Inc., with an indirect beneficial ownership of 1,979,173 shares of Class A Common Stock. The document was signed by Marc Larkins, Secretary of Johnson & Johnson, and underscores the company's significant investment in Contineum Therapeutics.
Johnson & Johnson, a major healthcare company, has filed an SEC Form 3 indicating an initial statement of beneficial ownership of securities. The filing, dated 04/09/2024, reveals that Johnson & Johnson, through its wholly-owned subsidiary Johnson & Johnson Innovation - JJDC, Inc., has become a 10% owner of Contineum Therapeutics, Inc., with an indirect beneficial ownership of 1,979,173 shares of Class A Common Stock. The document was signed by Marc Larkins, Secretary of Johnson & Johnson, and underscores the company's significant investment in Contineum Therapeutics.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.